Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-L1-CAM antibodies and uses thereof

An L1-CAM, antibody technology, applied in the direction of antibodies, antibody medical components, antibody mimics/stents, etc., can solve problems such as bystander toxicity

Pending Publication Date: 2020-05-01
MEMORIAL SLOAN KETTERING CANCER CENT
View PDF170 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although T cells can effectively target tumors with low levels of L1-CAM, there are concerns about potential bystander toxicity in normal tissues with low levels of L1-CAM expression
[0008] In addition to toxicity, regulation of cell harvesting, processing, storage, shipping, and product release for lymphocyte therapy can be challenging, especially when cells must be genetically modified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-L1-CAM antibodies and uses thereof
  • Anti-L1-CAM antibodies and uses thereof
  • Anti-L1-CAM antibodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0222] Preparation of polyclonal antisera and immunogens. Methods for producing antibodies or antibody fragments of the present technology generally include treating a subject (usually a non-human subject, such as a mouse or rabbits) for immunization. Suitable immunogenic preparations may contain, for example, recombinantly expressed L1-CAM protein or chemically synthesized L1-CAM peptide. Using standard techniques for polyclonal and monoclonal antibody preparation, the ECM of the L1-CAM protein or a portion or fragment thereof can be used as an immunogen to generate anti-L1-CAM antibodies that bind to the L1-CAM protein or a portion or fragment thereof.

[0223] The full length L1-CAM protein or fragments thereof can be used as fragments, as immunogens. 在一些实施方案中,L1-CAM片段包含氨基酸序列PKETVKPVEVEEGESVVLPCNPPPSAEPLRIYWMNSKILHIKQDERVTMGQNGNLYFANVLTSDNHSDYICHAHFPGTRTIIQKEPID(SEQ ID NO:74)(L1-CAM的Ig样C2型第2结构域)或TQITQGPRSTIEKKGSRVTFTCQASFDPSLQPSITWRGDGRDLQELGDSDKYFIEDGRLVIHSLDYSDQGNYSCVAST...

Embodiment 1

[0355] Example 1: Materials and Methods for Producing and Characterizing Anti-L1-CAM Antibodies of the Present Technology

[0356] Immunohistochemistry (IHC). The use of human tumor and normal tissues for IHC was approved by the Institutional Review Board of Memorial Sloan-Kettering Cancer Center. Five to seven micron sections of snap-frozen tissue were fixed in acetone at -20°C for 30 minutes. Endogenous biotin-binding activity was blocked by sequential treatment with avidin and biotin (Carrier Avidin-Biotin Blocking Kit; Invitrogen, Carlsbad, CA) for 20 min, followed by Each was blocked with 10% horse serum for 1 hour at room temperature. Sections were then stained sequentially with primary antibody, biotinylated horse anti-mouse IgG (H+L) (Vector Laboratories, Inc., Burlingame, CA) and avidin-biotin complex (Vectastain ABC kit, VectorVector Laboratories, Inc., Burlingame, CA) for 60 min at room temperature with washes between each reaction. Subsequently, sections were...

Embodiment 2

[0375] Example 2: Structure of the humanized anti-L1-CAM antibody of the present technology

[0376] Humanized E71 and E72 anti-L1-CAM antibodies were generated. Sequence design is based on human IgG homology calculations while retaining key mouse amino acid residues. Image 6 with Figure 7 The V of murine E71 is shown separately H and V L (represented as SEQ ID NO: 1 and 3) and the V of mouse E72 H and V L (Denoted as SEQ ID NO: 5 and 7). Mouse E71 (see Image 6 ) and E72 (see Figure 7 ) heavy and light chain CDRs were grafted onto the human IgG1 framework based on their homology to the human framework. For E71, the homologous human sequence used for the heavy chain was IGHV7-4-1 (SEQ ID NO:2), and the homologous human sequence used for the light chain was IGKV-58 (SEQ ID NO:4) ( Image 6 ). For E72, the homologous human sequences used for the heavy and light chains were IGHV1-2*02|66.3|IGHJ4*01|85.7 (SEQ ID NO: 6) and IGKV1-NL1*01|73.7|IGKJ2*02| 81.8 (SEQ ID N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein.The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 62 / 520,382, filed June 15, 2017, the disclosure of which is incorporated herein by reference in its entirety. [0003] sequence listing [0004] This application contains a Sequence Listing that has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on June 14, 2018, is named 115872-0375_SL.txt and is 147,283 bytes in size. technical field [0005] The present technology generally relates to the preparation and uses of immunoglobulin-related compositions (eg, antibodies or antigen-binding fragments thereof) that specifically bind L1-CAM proteins. In particular, the technology relates to the preparation of L1-CAM neutralizing antibodies and the use of said antibodies in the detection and treatment of L1-CAM-related cancers. Background technique [0006] The following description ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00C07K14/705C07K16/28
CPCC07K14/70503C07K16/2803C07K2319/21C07K2319/30C07K16/2809A61K2039/505C07K2317/21C07K2317/24C07K2317/31C07K2317/52C07K2317/622C07K2317/732C07K2317/92C07K2317/14C07K2317/41C07K2317/90A61P35/00A61K45/06C07K16/30C07K2317/54C07K2317/55C07K2317/76G01N33/534
Inventor N·K·张H·许M·铃木西岛B·奈米波卡J·刘易斯
Owner MEMORIAL SLOAN KETTERING CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com